BIO-Europe 2026
Talk Presenting Companies (Theatre A) track
Immuno-Oncology: Txinno Bioscience Inc.
Mon, Nov 9, 2026 · 2:45–3:00 PM CET Koelnmesse
About this session
Txinno Bioscience is a clinical-stage biotech company headquartered in Korea, specializing in small molecules and targeted protein degraders for cancer treatment. Txinno has recently received IND approval for a Phase 2 clinical trial of TXN10128 in Korea and advanced 2nd program, TXN12923, to the preclinical stage.
Speaker
-
BD Team Leader · Txinno Bioscience Inc.
Speaker